Kaken Pharmaceutical Co (TSE:4521) E10: 円370.46 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4521 Kaken Pharmaceutical Co Ltd TSE:4521
69 GF Score
Price 円3,900.00
GF Value 円3,775.44
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Kaken Pharmaceutical Co E10?

Kaken Pharmaceutical Co TSE:4521 +1.04% 69 E10 is 円370.46 as of Mar. 2026. GuruFocus rates TSE:4521 with a GF Score™ of 69/100 and a GF Value™ of 円3,775.44 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Kaken Pharmaceutical Co's adjusted earnings per share data for the three months ended in Mar. 2026 was 円19.700. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is 円370.46 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Kaken Pharmaceutical Co's average E10 Growth Rate was -11.20% per year. During the past 3 years, the average E10 Growth Rate was -1.90% per year. During the past 5 years, the average E10 Growth Rate was 0.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Kaken Pharmaceutical Co was 8.70% per year. The lowest was -1.90% per year. And the median was 2.60% per year.

As of today (2026-07-21), Kaken Pharmaceutical Co's current stock price is 円3900.00. Kaken Pharmaceutical Co's E10 for the quarter that ended in Mar. 2026 was 円370.46. Kaken Pharmaceutical Co's Shiller PE Ratio of today is 10.53.

During the past 13 years, the highest Shiller PE Ratio of Kaken Pharmaceutical Co was 22.05. The lowest was 8.02. And the median was 11.02.


Kaken Pharmaceutical Co  (TSE:4521) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Kaken Pharmaceutical Co's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=3900.00/370.46
=10.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Kaken Pharmaceutical Co was 22.05. The lowest was 8.02. And the median was 11.02.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Kaken Pharmaceutical Co E10 Related Terms


Kaken Pharmaceutical Co E10 Historical Data

* Premium members only.

The historical data trend for Kaken Pharmaceutical Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaken Pharmaceutical Co E10 Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 387.58 392.11 398.40 417.30 370.46

Kaken Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 417.30 403.00 389.01 372.28 370.46

TSE:4521 vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's Shiller PE Ratio falls into.


TSE:4521
69GF Score
Kaken Pharmaceutical Co Ltd TSE:4521
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kaken Pharmaceutical Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kaken Pharmaceutical Co's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=19.7/112.7000*112.7000
=19.700

Current CPI (Mar. 2026) = 112.7000.

Kaken Pharmaceutical Co Quarterly Data

per share eps CPI Adj_EPS
201606 140.050 98.100 160.893
201609 136.454 98.000 156.922
201612 157.876 98.400 180.819
201703 98.700 98.100 113.389
201706 133.810 98.500 153.100
201709 133.750 98.800 152.567
201712 148.500 99.400 168.370
201803 54.168 99.200 61.540
201806 100.160 99.200 113.791
201809 120.680 99.900 136.143
201812 136.000 99.700 153.733
201903 88.826 99.700 100.408
201906 121.650 99.800 137.374
201909 120.910 100.100 136.129
201912 154.110 100.500 172.818
202003 98.054 100.300 110.176
202006 98.180 99.900 110.760
202009 87.970 99.900 99.241
202012 96.540 99.300 109.568
202103 64.486 99.900 72.748
202106 87.780 99.500 99.425
202109 88.460 100.100 99.595
202112 93.170 100.100 104.898
202203 -18.430 101.100 -20.545
202206 76.910 101.800 85.145
202209 81.430 103.100 89.012
202212 84.970 104.100 91.990
202303 -98.978 104.400 -106.847
202306 66.990 105.200 71.766
202309 41.190 106.200 43.711
202312 68.841 106.800 72.644
202403 35.570 107.200 37.395
202406 46.320 108.200 48.246
202409 330.910 108.900 342.457
202412 129.080 110.700 131.412
202503 -140.890 111.100 -142.919
202506 7.130 111.700 7.194
202509 19.030 112.000 19.149
202512 10.710 113.000 10.682
202603 19.700 112.700 19.700

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of 円370.46 mean?
Kaken Pharmaceutical Co (TSE:4521) has a E10 of 円370.46 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Kaken Pharmaceutical Co and its competitors.
Is Kaken Pharmaceutical Co's E10 too high?
Kaken Pharmaceutical Co's current E10 is 円370.46. Overall, Kaken Pharmaceutical Co has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's E10 compare to ZTS and UTHR?
Kaken Pharmaceutical Co's E10 of 円370.46 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Kaken Pharmaceutical Co and its competitors. Kaken Pharmaceutical Co's current E10 is 円370.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co (TSE:4521) is currently considered Fairly Valued. The stock's GF Value™ is 円3,775.44, compared to a current price of 円3,900.00 — trading 3.3% above its estimated fair value. The current E10 is 円370.46. Kaken Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Kaken Pharmaceutical Co (TSE:4521), the current E10 is 円370.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kaken Pharmaceutical Co (TSE:4521) Overvalued in 2026?

Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued. The current stock price of 円3,900.00 is trading 3.3% above its estimated GF Value™ of 円3,775.44. GuruFocus considers Kaken Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4521:

  • E10: 円370.46
  • GF Value™: 円3,775.44 vs. price of 円3,900.00 (3.3% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the TSE:4521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kaken Pharmaceutical Co Business Description

Address 28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
69GF Score

Get the complete analysis for TSE:4521

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,900.00
Price
円3,775.44
GF Value